NCT05002127Phase 2, phase 3Active not recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-05-24Actual

Enrollment · participants127Actual

Source updated2025-08-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma

Treatments or interventions studied

Evorpacept (ALX148)Drug
TrastuzumabDrugAlso known as Herceptin
RamucirumabDrugAlso known as Cyramza
PaclitaxelDrugAlso known as Taxol

Primary outcomes · main study measures

measure: Phase 2; description: Percentage of patients with objective response per RECIST 1.1; timeFrame: Last randomized patient on study at least 16 weeks; measure: Phase 3; description: Overall Survival; timeFrame: From the date of randomization to the date of death (due to any cause), up to 36 months postdose

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history